NKGen Biotech, Inc.
nkgenbiotech.comWhat Do They Do?
Develops activated natural killer cell therapies for patients with neurodegenerative diseases and cancer.
10-K for FY2024, filed Oct 8, 2025
How Are They Changing?
- Net income
-
Sources
10-Q for Q1 FY2025, filed Jan 20, 2026
$15.4MView ↗
- ▲ Now profitable
- vs −$5.4M in Q1 FY2024
From blank check to cell therapy
The older report described a blank-check company seeking a business combination with no operations or revenue. The latest report describes a biotechnology company developing activated NK-cell therapies for neurodegenerative diseases and cancer.
10-K for FY2021, filed Mar 31, 2022 10-K for FY2024, filed Oct 8, 2025We are a blank check company incorporated on January 28, 2021 as a Delaware corporation for the purpose of effecting a merger, capital…View ↗
We are a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK…View ↗
Who Do They Compete With?
Competes with Acepodia, Artiva, Celularity, Century Therapeutics, Cytovia Therapeutics, Fate Therapeutics, Nkarta, ImmunityBio, Affimed, Innate Pharma, Dragonfly Therapeutics, and GT Biopharma
10-K for FY2024, filed Oct 8, 2025We currently face competition from Acepodia, Artiva, Celularity, Century Therapeutics, Cytovia Therapeutics, Fate Therapeutics, Nkarta, and…View ↗
Loading...
